ArticleMolecular neurodegeneration2007
APP-BP1 inhibits Abeta42 levels by interacting with Presenilin-1.
Article in Molecular neurodegeneration, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- The modifier matrix: emerging roles of ubiquitin-like proteins in Alzheimer's disease.Molecular neurodegeneration advances · 2026Review
- Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration.Cell stem cell · 2024Article
- Role of Neddylation in Neurodegenerative Diseases.NeuroSci · 2022Review
- The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention.Environmental science and pollution research international · 2020Review
- Cellular Proteostasis in Neurodegeneration.Molecular neurobiology · 2019Review
- Data-Driven Analysis of Age, Sex, and Tissue Effects on Gene Expression Variability in Alzheimer's Disease.Frontiers in neuroscience · 2019Article
- Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-β Accumulation in Mice.Journal of Alzheimer's disease : JAD · 2017Article
- Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration.The Journal of clinical investigation · 2016Article
- Cycle on Wheels: Is APP Key to the AppBp1 Pathway?Austin Alzheimer's and Parkinson's disease · 2014Article
- Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in β-amyloid generation and Alzheimer's disease.American journal of physiology. Heart and circulatory physiology · 2013Article
- Neddylation dysfunction in Alzheimer's disease.Journal of cellular and molecular medicine · 2012Review
- Cul4B regulates neural progenitor cell growth.BMC neuroscience · 2012Article
- Amyloid precursor protein binding protein-1 modulates cell cycle progression in fetal neural stem cells.PloS one · 2010Article
- Article
- Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2008Article
- Amyloid precursor protein modulates beta-catenin degradation.Journal of neuroinflammation · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe beta-amyloid precursor protein (APP) is sequentially cleaved by the beta- and then gamma-secretase to generate the amyloid beta-peptides Abeta40 and Abeta42. Increased Abeta42/Abeta40 ratios trigger amyloid plaque formations in Alzheimer's disease (AD). APP binds to APP-BP1, but the biological consequence is not well understood.
resultsWe report that when the endogenous APP-BP1 was suppressed by small interfering RNAs (siRNAs), cell-associated Abeta42 was dramatically increased in APP695 expressing primary neurons. The accumulation of Abeta42 was accompanied by significant increases in APP and APP-CTF in APP-BP1 siRNA expressing neurons. In contrast, APP-BP1 overexpression in primary neurons significantly decreased the levels of Abeta and endogenous APP but not APLPs. We also investigated the potential mechanism of APP-BP1-mediated APP processing. APP-BP1 co-precipitated with Presenilin-1 (PS1) in native rat brain extracts, co-migrated with the gamma-secretase components in brain membrane extracts in glycerol gradient centrifugation, and colocalized in primary neurons. Further, the endogenous PS1-CTF was significantly downregulated by APP-BP1 expression.
conclusionOur data suggest that APP-BP1 may inhibit Abeta42 production by interacting with PS1 under physiological conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.